Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
"nIntroduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer. "nPatient and Method: 32 eligible patients (median age 62, range 41-72) with measurable endometrial cancer were tr...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2009-07-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/16095.pdf&manuscript_id=16095 |
id |
doaj-3ce8c817fca6492c86563ae8832a435c |
---|---|
record_format |
Article |
spelling |
doaj-3ce8c817fca6492c86563ae8832a435c2020-11-25T03:56:33ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-30092008-22072009-07-013313Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial CancerHamid AttarianH RezvaniM GHadyaniS AttarianOkhovatianA Khosravi"nIntroduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer. "nPatient and Method: 32 eligible patients (median age 62, range 41-72) with measurable endometrial cancer were treated with Carboplatin (AUC= 6) and Paclitaxel (175 mg/m3) every 4 weeks for 6 cycles, or, until disease progression or severe toxicity. "nResult: The ORR was 54% (16 out of 30), CR in 4 and PR in 12. "nThe median progression free survival was 8.2 months. The 6 months overall survival was seen in 80% of trhe patients. The toxicity was generally tolerable. "nConclusion: The combination of Carboplatin plus Paclitaxel was well tolerated in this trial. This regimen demonstrated feasible success in curing advanced endometrial cancer compared to other combination therapies used before (in terms of RR and toxicity). http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/16095.pdf&manuscript_id=16095 Endometrial cancer, Carboplatin, Paclitaxel |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hamid Attarian H Rezvani M GHadyani S Attarian Okhovatian A Khosravi |
spellingShingle |
Hamid Attarian H Rezvani M GHadyani S Attarian Okhovatian A Khosravi Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer International Journal of Hematology-Oncology and Stem Cell Research Endometrial cancer, Carboplatin, Paclitaxel |
author_facet |
Hamid Attarian H Rezvani M GHadyani S Attarian Okhovatian A Khosravi |
author_sort |
Hamid Attarian |
title |
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer |
title_short |
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer |
title_full |
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer |
title_fullStr |
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer |
title_full_unstemmed |
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer |
title_sort |
carboplatin plus paclitaxel in the first line therapy of recurrent and advances endometrial cancer |
publisher |
Tehran University of Medical Sciences |
series |
International Journal of Hematology-Oncology and Stem Cell Research |
issn |
2008-3009 2008-2207 |
publishDate |
2009-07-01 |
description |
"nIntroduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer. "nPatient and Method: 32 eligible patients (median age 62, range 41-72) with measurable endometrial cancer were treated with Carboplatin (AUC= 6) and Paclitaxel (175 mg/m3) every 4 weeks for 6 cycles, or, until disease progression or severe toxicity. "nResult: The ORR was 54% (16 out of 30), CR in 4 and PR in 12. "nThe median progression free survival was 8.2 months. The 6 months overall survival was seen in 80% of trhe patients. The toxicity was generally tolerable. "nConclusion: The combination of Carboplatin plus Paclitaxel was well tolerated in this trial. This regimen demonstrated feasible success in curing advanced endometrial cancer compared to other combination therapies used before (in terms of RR and toxicity). |
topic |
Endometrial cancer, Carboplatin, Paclitaxel |
url |
http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/16095.pdf&manuscript_id=16095 |
work_keys_str_mv |
AT hamidattarian carboplatinpluspaclitaxelinthefirstlinetherapyofrecurrentandadvancesendometrialcancer AT hrezvani carboplatinpluspaclitaxelinthefirstlinetherapyofrecurrentandadvancesendometrialcancer AT mghadyani carboplatinpluspaclitaxelinthefirstlinetherapyofrecurrentandadvancesendometrialcancer AT sattarian carboplatinpluspaclitaxelinthefirstlinetherapyofrecurrentandadvancesendometrialcancer AT okhovatian carboplatinpluspaclitaxelinthefirstlinetherapyofrecurrentandadvancesendometrialcancer AT akhosravi carboplatinpluspaclitaxelinthefirstlinetherapyofrecurrentandadvancesendometrialcancer |
_version_ |
1724464450875949056 |